株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脳卒中:パイプライン製品の分析

Stroke - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 229744
出版日 ページ情報 英文 450 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
脳卒中:パイプライン製品の分析 Stroke - Pipeline Review, H2 2017
出版日: 2017年10月31日 ページ情報: 英文 450 Pages
概要

脳卒中とは、酸素不足のために脳細胞が突然死するという症状です。症状は突然かつ急速に生じ、短時間(通常は数分〜数時間)で終了します。最初のうちは、患者は体調が悪く感じ、顔面が蒼白となり、気分も非常に悪くなります。また、突然の頭痛に悩まされることもあります。突然に顔面や手足、特に身体の片側が痺れる場合もあります。ろれつが回らない、話された内容を理解できない、視力が低下する、歩いたりバランスを取るのが難しくなる、という症状が出ることもあります。

当レポートでは、世界各国での脳卒中治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

脳卒中の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9848IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H2 2017, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 24, 15, 1, 86, 11 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 32 and 3 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Stroke - Overview
  • Stroke - Therapeutics Development
  • Stroke - Therapeutics Assessment
  • Stroke - Companies Involved in Therapeutics Development
  • Stroke - Drug Profiles
  • Stroke - Dormant Projects
  • Stroke - Discontinued Products
  • Stroke - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Stroke, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Stroke - Pipeline by Acorda Therapeutics Inc, H2 2017
  • Stroke - Pipeline by Acticor Biotech SAS, H2 2017
  • Stroke - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2017
  • Stroke - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Stroke - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2017
  • Stroke - Pipeline by Affibody AB, H2 2017
  • Stroke - Pipeline by Anavex Life Sciences Corp, H2 2017
  • Stroke - Pipeline by Angion Biomedica Corp, H2 2017
  • Stroke - Pipeline by Antoxis Ltd, H2 2017
  • Stroke - Pipeline by AptaTargets SL, H2 2017
  • Stroke - Pipeline by ArmaGen Inc, H2 2017
  • Stroke - Pipeline by Artielle ImmunoTherapeutics Inc, H2 2017
  • Stroke - Pipeline by Athersys Inc, H2 2017
  • Stroke - Pipeline by Bayer AG, H2 2017
  • Stroke - Pipeline by Biogen Inc, H2 2017
  • Stroke - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Stroke - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Stroke - Pipeline by Cardax Inc, H2 2017
  • Stroke - Pipeline by CHA Bio & Diostech Co Ltd, H2 2017
  • Stroke - Pipeline by D-Pharm Ltd, H2 2017
  • Stroke - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
  • Stroke - Pipeline by DiaMedica Therapeutics Inc, H2 2017
  • Stroke - Pipeline by Diffusion Pharmaceuticals Inc, H2 2017
  • Stroke - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Stroke - Pipeline by Fina Biotech SL, H2 2017
  • Stroke - Pipeline by Genervon Biopharmaceuticals LLC, H2 2017
  • Stroke - Pipeline by Glialogix Inc, H2 2017
  • Stroke - Pipeline by Glucox Biotech AB, H2 2017
  • Stroke - Pipeline by Green Cross Corp, H2 2017
  • Stroke - Pipeline by Huons Global Co Ltd, H2 2017
  • Stroke - Pipeline by Immunwork Inc, H2 2017
  • Stroke - Pipeline by International Stem Cell Corp, H2 2017
  • Stroke - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
  • Stroke - Pipeline by JN-International Medical Corp, H2 2017
  • Stroke - Pipeline by JT Pharmaceuticals Inc, H2 2017
  • Stroke - Pipeline by Les Laboratoires Servier SAS, H2 2017
  • Stroke - Pipeline by Living Cell Technologies Ltd, H2 2017
  • Stroke - Pipeline by Lumosa Therapeutics Co Ltd, H2 2017
  • Stroke - Pipeline by M et P Pharma AG, H2 2017
  • Stroke - Pipeline by Magnus Life Ltd, H2 2017
  • Stroke - Pipeline by Mapreg SAS, H2 2017
  • Stroke - Pipeline by Medestea Research & Production SpA, H2 2017
  • Stroke - Pipeline by Meridigen Biotech Co Ltd, H2 2017
  • Stroke - Pipeline by Neuralstem Inc, H2 2017
  • Stroke - Pipeline by Neuren Pharmaceuticals Ltd, H2 2017
  • Stroke - Pipeline by Neurofx Inc, H2 2017
  • Stroke - Pipeline by Neuronax SAS, H2 2017
  • Stroke - Pipeline by NeuroSearch A/S, H2 2017
  • Stroke - Pipeline by New World Laboratories Inc, H2 2017
  • Stroke - Pipeline by NoNO Inc, H2 2017
  • Stroke - Pipeline by Novartis AG, H2 2017
  • Stroke - Pipeline by Noxopharm Ltd, H2 2017
  • Stroke - Pipeline by NuvOx Pharma LLC, H2 2017
  • Stroke - Pipeline by Omniox Inc, H2 2017
  • Stroke - Pipeline by Panacea Pharmaceuticals Inc, H2 2017
  • Stroke - Pipeline by Pharmagenesis Inc, H2 2017
  • Stroke - Pipeline by Pharmaxis Ltd, H2 2017
  • Stroke - Pipeline by Pharmicell Co Ltd, H2 2017
  • Stroke - Pipeline by Phoenix Biotechnology Inc, H2 2017
  • Stroke - Pipeline by PhytoHealth Corp, H2 2017
  • Stroke - Pipeline by Pluristem Therapeutics Inc, H2 2017
  • Stroke - Pipeline by ReCyte Therapeutics Inc, H2 2017
  • Stroke - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
  • Stroke - Pipeline by ReNeuron Group Plc, H2 2017
  • Stroke - Pipeline by Rubicon Biotechnology Inc, H2 2017
  • Stroke - Pipeline by SanBio Inc, H2 2017
  • Stroke - Pipeline by Saneron CCEL Therapeutics Inc, H2 2017
  • Stroke - Pipeline by Savara Inc, H2 2017
  • Stroke - Pipeline by Shin Poong PharmCo Ltd, H2 2017
  • Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2017
  • Stroke - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
  • Stroke - Pipeline by Stemedica Cell Technologies Inc, H2 2017
  • Stroke - Pipeline by SynZyme Technologies LLC, H2 2017
  • Stroke - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
  • Stroke - Pipeline by Tenax Therapeutics Inc, H2 2017
  • Stroke - Pipeline by TikoMed AB, H2 2017
  • Stroke - Pipeline by Verseon Corp, H2 2017
  • Stroke - Pipeline by Vicore Pharma AB, H2 2017
  • Stroke - Pipeline by Virogenomics BioDevelopment Inc, H2 2017
  • Stroke - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017
  • Stroke - Pipeline by Zocere Inc, H2 2017
  • Stroke - Dormant Projects, H2 2017
  • Stroke - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Stroke - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Stroke - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Stroke - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Stroke - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Stroke - Dormant Projects, H2 2017 (Contd..6), H2 2017
  • Stroke - Dormant Projects, H2 2017 (Contd..7), H2 2017
  • Stroke - Dormant Projects, H2 2017 (Contd..8), H2 2017
  • Stroke - Dormant Projects, H2 2017 (Contd..9), H2 2017
  • Stroke - Discontinued Products, H2 2017
  • Stroke - Discontinued Products, H2 2017 (Contd..1), H2 2017
  • Stroke - Discontinued Products, H2 2017 (Contd..2), H2 2017

List of Figures

  • Number of Products under Development for Stroke, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top